What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD

• https://x.com/drdavidliew/status/1982852265397653571/photo/1

Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

• https://x.com/RichardPAConway/status/1982852038548406493/photo/1

Fragoulis et al. Real world study of bimekizumab demonstrates equal efficacy in IL-17i naive and exposed. @RheumNow #ACR25 Abstr#1439 https://t.co/aCcLgnKvFJ

• https://x.com/RichardPAConway/status/1982851535177707738/photo/1

Gensler et al. Bimekizumab in male and female axSpA patients. Greater benefit in males at week 16, but similar responses at week 52 @RheumNow #ACR25 Abstr#1449 https://t.co/zDYI2zItqT

• https://x.com/RichardPAConway/status/1982850528640917998/photo/1

Getting RA patients into remission: have we plateaued? @MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y Surely we can aspire to more? Let’s target barriers to implementing better #ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet

• https://x.com/drdavidliew/status/1982850367370211807/photo/1

Mac Gearailt et al. Depression in axSpA. Depression in 10%. Associated higher disease activity, worse functional status, and increased peripheral manifestations. @RheumNow #ACR25 Abstr#1409 https://t.co/8pnoQiaiQr

• https://x.com/RichardPAConway/status/1982849018951536757/photo/1

Kharouf et al. Effect of handedness on radiographic damage in PsA. Left-handedness associated increased peripheral damage, especially in left hand. Hypothesis that having to use tools designed for right-handedness increases mechanical stress @RheumNow #ACR25 Abstr#1415 https://t.co/gfGQkrYyc8

• https://x.com/RichardPAConway/status/1982848012193018147/photo/1

Bimekizumab showed sustained 1-year efficacy in axSpA across age, BMI, CRP, and HLA-B27 subgroups. ASAS40, ASDAS, BASDAI, ASQoL, and MRI scores improved in most groups—especially age ≤35, BMI 25–30, CRP >5, and HLA-B27+. Abstract 1451 @RheumNow #ACR25

In Sjögren’s, cancer risk is real. >9yr multicenter cohort (n=314), overall cancer risk ↑ (SIR 1.68), NHL >15× expected Predictors: older age, smoking, LAD, splenomegaly, cryoglobulinemia (strongest for lymphoma). Malignancies = 24% of deaths @RheumNow #ACR25 Abstract #1681

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

• https://x.com/RichardPAConway/status/1982845746950164581/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

• https://x.com/RichardPAConway/status/1982844488977437109/photo/1

I wouldn't sleep on this. 😴💤 Abstract 1413: In a PsA cohort, restless leg syndrome was linked to: 🔹 ↑ disease activity (polyarthritis, swollen joints, DAPSA) 🔹 Worse physical function (↑ HAQ) 🔹 Fatigue, anxiety, depression, & poorer sleep quality @RheumNow #ACR25

Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43 Ongoing research, further data needed. #ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW

• https://x.com/RHEUMarampa/status/1982843734011105721/photo/1

Really useful observational study, 305 pts with TAK Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory Majority of lesions stenotic. Emphasizes importance of regular monitoring #ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym

• https://x.com/EBRheum/status/1982843733952385436/photo/1
• https://x.com/EBRheum/status/1982843733952385436/photo/1